Radiotherapy combined with immunotherapy for esophageal cancer: current status and challenge Authors: Yuqing Wang, Junjie Gu, Xinchen Sun Published: 2026 ABSTRACT AbstractWith the advent of the immunotherapy era, the combination of radiotherapy and immunotherapy has become a critical strategy to enhance patient outcomes. In addition to its direct cytotoxicity, radiotherapy modulates the immune response within the tumor and its surrounding microenvironment by stimulating the body’s anti-tumor immune response. This interplay provides the rationale for combining radiotherapy with immunotherapy. This review will summarize the immunomodulatory mechanisms of radiation therapy, evaluate the clinical efficacy and safety of combining radiotherapy with immunotherapy, and outline its current applications, challenges, and future potential. In the future, the combination of radiotherapy and immunotherapy holds immense potential in esophageal cancer treatment. Through additional prospective clinical trials exploring optimal combinations, timing, and biomarkers, we can further refine treatment strategies and enhance patient survival.Supplementary InformationThe online version contains supplementary material available at 10.1007/s00432-026-06480-2.Keywords: Esophageal cancer, Radiotherapy, Immunotherapy, Immunomodulation Introduction According to 2022 global cancer statistics, esophageal cancer (EC) ranked as the seventh leading cause of cancer-related deaths (Bray et al. 2024). Due to its high incidence rate, treatment difficulties, and generally poor outcomes, EC has become a major global public health challenge. Surgery is the standard treatment for early EC. However, since EC lacks evident clinical symptoms in early stages, most patients are not diagnosed early enough to receive timely surgical treatment. Radiotherapy (RT) is a primary modality for locally definitive treatment, and also plays an important role in the comprehensive treatment of locally advanced and advanced EC. The basis of RT is to directly kill tumor cells. In recent years, it has been found that RT can also modulate the tumor immune microenvironment through complex mechanisms and induce an anti-tumor immune response. Notably, the effect of RT on the tumor immune microenvironment is a double-edged sword (Berzaghi et al. 2019; McLaughlin et al. 2020): it can stimulate or suppress the tumor immune microenvironment, and the final effect depends on many factors, such as pre-existing immune context, dose and fractionation regimen. With the rapid advancement of cancer immunotherapy, immune checkpoint inhibitors (ICIs) have shown potential in the treatment of cancer by opening up new possibilities in the comprehensive treatment of malignant tumors (Kwantwi 2023). Although ICIs are changing the cancer treatment landscape, only a few patients currently benefit from them. In this case, the combination of radiotherapy and immunotherapy has broad prospects. It has been found that RT can improve the effectiveness of ICIs by upregulating the expression of PD-L1 (Programmed Cell Death Ligand 1) in the tumor microenvironment (TME), and ICIs may magnify the biological effects of RT (Li et al. 2025b). The possible synergistic mechanism provides a rational basis for the combination therapy. Recently, neoadjuvant immunochemoradiotherapy (nICRT) has shown potential as a new treatment modality for resectable EC. With the deep understanding of the immunomodulatory effects of RT, the research on RT combination therapies has developed rapidly, and it has high expectations for the treatment effect of RT. In addition, with the continuous emergence of highly effective novel immunotherapy agents, RT, as an important component of combination strategies, has attracted a lot of attention and opened up new research directions. In this review, we summarize the immunomodulatory effects of RT, discuss the current status and strategies of its combination with immunotherapy, and finally discuss the main challenges and future research directions. RT immunomodulation Traditionally, the anti-tumor effect of RT was mainly thought to come from direct cytotoxic effects, and its core mechanism involves inducing DNA damage in tumor cells, which leads to cell cycle arrest and death, thereby inhibiting tumor growth. In addition, RT can also regulate tumor metabolism, angiogenesis, and the tumor microenvironment, thereby further regulating tumor biological behavior. With the development of tumor immune microenvironment research, the immunomodulatory effect of RT has attracted increasing attention. At present, experimental evidence has confirmed that RT can activate anti-tumor immune response, and its mechanism provides strong basis for combination immunotherapy. The key mechanisms are illustrated in Figs. 1 and 2. Radiation reshapes the tumor microenvironment, leading to anti-tumor or pro-tumor effects. In the tumor microenvironment, radiation stimulates tumor cells to release antigens. These antigens are captured by dendritic cells, which then activate CD8 + T cells, or activate neutrophils and NK cells by generating ROS, thereby generating anti-tumor effects. Furthermore, tumor cells at different locations, of different types, or exposed to different doses of radiation can activate MDSCs, TAMs, and Treg cells through various pathways, inhibiting the function of CD8 + T cells, thereby promoting the survival and growth of the tumor The pattern diagram of abscopal effect, radscopal effect and homing signal caused by irradiation. The abscopal effect refers to the phenomenon where radiation is applied to tumor cells, resulting in the production of a large number of immunogens, exosomes, and other substances. These substances activate dendritic cells, lymphocytes, etc., thereby generating cytotoxic lymphocytes that can eliminate distant tumor cells. The radscopal effect refers to the phenomenon where, after irradiation, the cytokines secreted by tumor cells guide immune cells to distant tumor cells. The homing signal is the process by which radiation-generated DAMPs stimulate T cells in the circulatory system to return to their specific locations The Impact of RT on the TME The TME is widely recognized as a complex ecological environment comprising different cells, extracellular matrix, blood vessels and immune cells around tumor cells. They interact with tumor cells and affect tumor growth, invasion, and response to treatment (Jung and Paust 2024). These changes will directly affect the immune cells around the tumor, including dendritic cells (DCs), T cells, macrophages, and so on, to regulate the antitumor immune response. In this article, we will discuss how RT affects the non-tumor cells in the TME (Fig. 1), exploring both its anti-tumor and pro-tumor effects. We will discuss its impact on immune cells and blood vessels, how these changes affect RT efficacy, and their potential to induce a systemic immune response, similar to an “in situ vaccine” effect (Formenti and Demaria 2012). When it comes to the anti-tumor effects of radiation, cancer cells are injured by this treatment in two main ways: direct disruption of DNA by rays and the generation of reactive oxygen species (ROS) (Zhang et al. 2022). Changes in the local immune microenvironment, including increased T cell infiltration within the tumor and alterations in the polarization state of tumor-associated macrophages, may transform “cold” tumors (immunologically inactive) into “hot” tumors (immunologically active) (McLaughlin et al. 2020), which may be a prerequisite for responses to ICIs. In addition, RT can also enhance the infiltration of T cells in the tumor and activate these T cells. It may even induce the formation of immune memory (Baxevanis et al. 2022). Tumor-resident T cells may be relatively resistant to RT and can survive at high doses to participate in the local antitumor immune response, while CD8 + T cells in lymph nodes are more sensitive to RT (Marciscano et al. 2018; Arina et al. 2019; Luo et al. 2023). A balance exists between the direct cytotoxic effects of RT and its immunostimulatory effects that drive T cell priming and activation (Arina et al. 2019). Different radiation doses and fractionation regimens may have different effects on T cell activation and function. The immune-activating effects of RT are dose- and fractionation-dependent. Preclinical studies suggest that hypofractionated regimens may enhance immunogenic cell death and T cell priming compared to conventional fractionation (Vanpouille-Box et al. 2017; Sridharan 2022; Zhang et al. 2023). As mentioned before, RT can also cause the formation of ROS and reactive nitrogen to mediate the activation and recruitment of innate immune effectors. This includes activated neutrophils and natural killer cells, which initiate phagocytosis and cytotoxic reactions (Wirsdörfer et al. 2018). This process clears cell debris and damaged cells, preparing the tissue for repair and further immune activation. RT promotes the maturation and activation of DCs through damage-associated molecular patterns (DAMPs), enhancing their ability to present tumor antigens and activate CD4 + and CD8 + T cell responses (Böttcher et al. 2018). RT also stimulates tumor cells and stromal cells to release cytokines and chemokines that attract and activate immune cells, shifting the TME away from immunosuppression. Notably, EC is characterized by an abundance of tumor-associated antigens and neoantigens within its TME. These antigens can be captured and presented by DCs to activate cytotoxic T lymphocytes, ultimately triggering a robust antitumor immune response (Huang and Fu 2019). On the contrary, RT can also promote an immunosuppressive environment by altering the cytokine profile within the TME. For example, as shown in Fig. 1, RT increases myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs). The number of MDSCs may increase or decrease after RT depending on tumor models, radiation dose, and irradiated sites. The CSF1/CSF1R signaling pathway is essential for MDSC infiltration, and inhibiting this pathway can reduce tumor recurrence after RT (Zhu et al. 2022). RT can activate monocytes and tissue macrophages, promoting their differentiation into M1 or M2 macrophages (Coates et al. 2008). Cancer-associated fibroblasts (CAFs) can suppress M1 macrophage function by downregulating M1 surface markers (Berzaghi et al. 2019; Zhu et al. 2022). After RT, there is a significant increase in Treg cell infiltration, which may be related to activation of the STAT3 pathway that promotes conversion of CD4 + T cells into Tregs (Zhang et al. 2022). Given the high radiosensitivity of lymphocytes, RT may result in the depletion of tumor-specific T cells, biasing the immune environment towards a more resistant state (Barker et al. 2015). Moreover, disparities in radiosensitivity among lymphocytes from different sites may further impact therapeutic outcomes (Cytlak et al. 2022). T cell exhaustion after RT also greatly influences the timing of combination immunotherapy. If T cells are exhausted, immune intervention during this window may not be effective. The best synergy may occur when treatment is combined during T cell recovery or immune remodeling.Consistent with these findings, single-cell sequencing studies have revealed an immunosuppressive landscape in esophageal squamous cell carcinoma dominated by exhausted T/NK cells, regulatory T cells, and M2 macrophages, and have identified the immunosuppressive network formed between Tregs and macrophages through the IL1R2 and LILRB1 axis as a potential therapeutic target (Zheng et al. 2020). Therefore, given the potential mechanisms of RT’s impact on peripheral blood lymphocytes, optimizing radiation modalities, target volume protocols, and radiation dosing holds substantial promise for reducing the risk of radiation-induced lymphopenia and maximizing the immunomodulatory effects of radiotherapy in EC (Wang et al. 2020b). In summary, RT has significant effects on the composition and structure of the TME, and these effects are dependent on dosage, location, and tumor type. Therefore, studies have proposed several potential therapeutic strategies, including immune checkpoint blockade, inhibition of soluble factors, anti-angiogenic therapy, and inhibition of DNA damage response, among others (Donlon et al. 2021). It is necessary to understand how RT affects the process of modulating the immune system and the mechanisms underlying these effects. Such information may provide guidance for developing new therapies that combine RT with the stimulation of the immune response to improve therapeutic effects. Abscopal effect RT primarily achieves local tumor control by directly damaging tumor cell DNA. It can also indirectly elicit a systemic anti-tumor immune response by enhancing the release and presentation of tumor antigens and activating immune cells. This indirect action is termed the “abscopal effect”, referring to the regression of distant metastatic lesions that have not been irradiated following RT at a localized site. The abscopal effect was first reported in 1953 (Xia et al. 2020). Over the past decades, it was considered an interesting but extremely rare phenomenon with limited clinical application prospects, largely because it is uncommon and unpredictable when RT is used alone. From 1969 to 2014, merely 46 instances of this phenomenon were documented (Ngwa et al. 2018). With the advancement of cancer immunotherapy, there has been a renewed interest in the abscopal effect, as it has been found that the combination of RT with immunostimulatory agents or immunotherapies significantly increases the incidence of the abscopal effect in patients (Demaria et al. 2004). The occurrence of the abscopal effect is associated with a variety of mechanisms, such as immunogenic cell death induced by RT, the antigen presentation process mediated by DCs, and the systemic migration of activated T cells and natural killer cells. Although the appearance of positive abscopal effects has been observed in mouse models (Arina et al. 2020), the incidence and persistence of the abscopal effects in human patients are usually low. Some reports showed that only small populations of patients may respond to this treatment (Luke et al. 2018). Preclinical studies usually use the “two-flank” mouse tumor model. Only one tumor is irradiated. The other tumor (the abscopal tumor) is used to evaluate the distant effect. However, this model may not reflect the situation of human metastatic cancer (Arina et al. 2020). The existence of heterogeneity of human tumors may be the reason that we rarely observe the abscopal effect in clinic practice. Maybe, different metastatic lesions have different genomic alterations, different clonal compositions and different immunogeneicity, which affect the effect of immunotherapy. Studies suggest that exosomes can enhance the abscopal effect of RT, although the specific mechanisms remain unclear (Yin et al. 2021). RT can affect the release and composition of exosomes from irradiated cells, which in turn can influence the cellular immune status. Clinically, the abscopal effect has been documented in EC, though rarely. A case report described a postoperative EC patient with lymph node metastases who achieved complete regression of all metastatic nodes after receiving 42 Gy in 6 daily fractions to a single lesion, suggesting that high-dose hypofractionated radiation may trigger this effect (Zhao et al. 2018). While such reports highlight the potential of the abscopal effect as a therapeutic option, further research is needed to make it clinically relevant and reproducible in EC patients. Ongoing studies are exploring whether combining RT with immunotherapy can increase the frequency of abscopal responses, particularly in the metastatic setting (Bruton Joe and Truong 2018; Takehara et al. 2023). Radscopal effect In addition to the abscopal effect, researchers have identified a related interesting phenomenon termed the “radscopal effect”. Some studies have proposed the concept that low-dose RT may enhance antitumor immune responses by reprogramming the TME, a phenomenon referred to as the “radscopal effect” (Barsoumian et al. 2020). The “radscopal effect,” a concept introduced by James Welsh (Zhang et al. 2022), describes a therapeutic strategy that synergistically combines high-dose stereotactic radiotherapy with low-dose irradiation to elicit systemic antitumor immunity. This effect may be realized by modifying the composition and role of immune cells within the TME, which involves the promotion of M1 macrophage polarization, the reduction of TGF-β levels, the activation and infiltration of CD4 + T cells, as well as an elevation in the proportion and activity of NK cells. Typically, conventional radiation therapy generates powerful immunosuppressive substances. In contrast, low-dose RT could be an effective approach to overcome these drawbacks. Low-dose RT causes mild DNA damage that does not trigger cell death but can activate danger signals and DAMPs to stimulate immune reactions (Mavragani et al. 2016). Unlike the rare abscopal effect, the radscopal effect may overcome immunosuppressive barriers in distant tumor sites. Low-dose RT increases chemokine secretion, boosting the release of chemokines that attract T cells, like CXCL9, CXCL10, CXCL11, CCL4, and CCL5 (Yin et al. 2020). This draws CD8 + T cells to distant tumor sites and remodels the TME. Low-dose RT supports T cells, NK cells, and M1 macrophages while raising immunostimulatory factors like NKG2D and its ligands and reducing inhibitory factors (Barsoumian et al. 2020). The radscopal effect remains a preclinical concept, but it highlights the importance of dose and fractionation in shaping immune responses. High-dose radiation (> 60 Gy) has been associated with improved overall survival and locoregional control in EC, whereas low-dose radiation may be effective in specific clinical scenarios. Studies suggest that low-dose radiation is effective for ESCC; conversely, a higher dose of 45–50.4 Gy may be required for EAC to achieve increased rates of pathological complete response (Mantziari et al. 2024). For elderly patients, careful consideration must be given to treatment tolerance and the risk of severe complications, necessitating a careful balance between the potential benefits of high-dose regimens and treatment-related toxicity. In the palliative setting, low-dose radiation may help alleviate symptoms such as dysphagia (Vermeulen et al. 2020); however, its capacity to effectively induce antitumor immune responses remains uncertain. Clinical translation of the abscopal effect would require meticulous patient selection and dosimetric planning to minimize excessive exposure of normal tissues. Homing signal Meanwhile, in the abscopal effect, homing signals are also of interest. Homing signals typically refer to signals that guide objects or cells to specific destinations. In immunology, homing signals are a key factor in the migration of immune cells, like T cells, to specific tissues or organs. These signals include cell surface adhesion molecules that help immune cells interact with endothelial cells, allowing them to pass through the vascular wall and enter the tissue. For instance, CD6 and CD166 are important molecules that regulate immune cell homing (Chappell et al. 2015). RT can affect the homing of immune cells, that is, their ability to migrate to the TME through multiple mechanisms. This includes triggering immunogenic cell death, which causes tumor cells to release DAMPs, as well as releasing chemokines to promote the homing of effector T cells to tumors. RT can modulate homing signals, which are responsible for the migration of effector T cells to the tumor site and the enhancement of antitumor immunity. It also modulates tumor vascular structure and microenvironment, further influencing immune cell homing. For example, RT can modulate the expression of CXC-chemokine receptor 3 (CXCR3) ligands inside tumors, which are involved in T cell homing (Charpentier et al. 2022). One study (Cytlak et al. 2022) indicated that there are possible homing signals between the lungs and intestinal mucosa, carried by immune cells in lymphoid tissue, which may enhance the transfer of immune cells between different organs and could be one mechanism of the abscopal effect. Homing signals are critical for T cell trafficking to tumors, and this process can be influenced by radiation exposure to immune-related organs. Studies have shown that dose-volume parameters of organs such as the lung, heart, and spleen can predict grade 4 radiation-induced lymphopenia in EC patients undergoing chemoradiotherapy (Chu et al. 2024). Since lymphopenia depletes the pool of circulating T cells available for homing to the tumor, protecting these organs through advanced radiotherapy techniques (e.g., IMRT, proton therapy) may preserve lymphocyte counts and facilitate effective T cell homing, thereby enhancing the efficacy of combined RT-immunotherapy. In summary, these findings demonstrate that RT could initiate a specific immune response. This not only improves the mechanistic understanding of the immunomodulatory effect of RT, but also provides a solid theoretical basis and new strategic directions for the clinical application of combining RT and immunotherapy. Efficacy and safety of radioimmunotherapy Although the synergistic interaction between RT and immunotherapy holds critical importance in contemporary oncology research (McLaughlin et al. 2020), the clinical application of this combination for EC has not yet been fully established. This concept is partially founded on the “abscopal effect,” a phenomenon where localized RT can elicit systemic anti-tumor immune responses (Arina et al. 2020). To understand the current evidence, it is useful to distinguish between different treatment settings. In recent years, multiple clinical studies have emerged to investigate the efficacy and safety of combining radiotherapy and immunotherapy, especially immunotherapy with ICIs, for the treatment of EC. Based on a systematic search of ClinicalTrials.gov over the past five years, we summarized the relevant clinical trials registered during this period. Table 1 lists the trials for which results have been reported, while Table S1 lists those that are registered but have no publication to date. Table 1Reported clinical trials investigating the combination of radiotherapy and immune checkpoint inhibitors in esophageal cancerRegistrationTrial phaseTumor typeStudy cohortControl cohortPrimary endpointsEstimated/ actual study completion dateStatusReferenceNeoadjuvant therapyNCT06637163IIESCCBenmelstobart + Paclitaxel + Carboplatin + RTPaclitaxel + Carboplatin + RTpCRApril, 2027RecruitingTang et al. (2026)NCT06303583I/IIESCCTislelizumab + Paclitaxel + Carboplatin + RT–pCRDecember 31, 2026Enrolling by invitationJiang et al. (2025)NCT05941481IIGEJATislelizumab + Capecitabine + Oxaliplatin + RT–pCRJune, 2026Active, not recruitingLi et al. (2025a, b)NCT03322267IILocally advanced ESCCPembrolizumab + cisplatin + RT–RFSDecember 30, 2025Active, not recruitingHsu et al. (2021)NCT03165994IIResectable EC/GEJCSotigalimab + paclitaxel + carboplatin + RT–pCRFebruary 21, 2023CompletedGuo et al. (2024)NCT03044613IbResectable EC/GEJCNivolumab + relatlimab + carboplatin + paclitaxel + RTNivolumab + carboplatin + paclitaxel + RTAEAugust, 2027Active, not recruitingKelly et al. (2024)NCT04568200IILocally advanced unresectable ESCCDurvalumab + carboplatin + paclitaxel + RTCarboplatin + paclitaxel + RTtumor response, pathological responseJanuary, 2024CompletedWang et al. (2025)NCT04776590IIResectable ECTislelizumab + carboplatin + albumin paclitaxel + RT–pCRDecember 15, 2024Active, not recruitingYang et al. (2023)NCT04974047IIResectable ESCCTislelizumab + cisplatin + paclitaxel + RTTislelizumab + cisplatin + paclitaxelpCROctober 25, 2024CompletedChen et al. (2023)NCT05043688IIILocally advanced ESCCCamrelizumab + carboplatin + albumin paclitaxel + RTCamrelizumab + carboplatin + albumin paclitaxelCarboplatin + albumin paclitaxel + RTEFSDecember 31, 2030RecruitingYang et al. (2022)NCT05189730IILocally advanced ESCCTislelizumab + carboplatin + paclitaxel + RT–pCR, AEDecember 31, 2023Active, not recruitingHe et al. (2022)Definitive therapyNCT04821778IIIESCC/EAC/GEJCPlatinum + Paclitaxel + 5-FU + Nimotuzumab + Anti-PD-1/PD-L1 Antibody + RTPlatinum + Paclitaxel + 5-FU + RTOSDecember 31, 2025RecruitingYang et al. (2025)NCT07015489IILocally advanced ESCCCamrelizumab + Paclitaxel + Carboplatin + RT-PFSMay, 2025CompletedChen et al. (2026)NCT05821452IILocally advanced unresectable ESCCCamrelizumab + Paclitaxel + Cisplatin + RTCamrelizumab + Paclitaxel + CisplatinR0 removal rate, MPRMay 30, 2026Not yet recruitingChen et al. (2024)NCT06061146IILocally advanced ESCCTislelizumab + S-1 + RTS-1 + RTPFSOctober, 2026RecruitingZhang et al. (2024)NCT03957590IIILocally advanced ESCCTislelizumab + Paclitaxel + cisplatin + RTPlacebo + Paclitaxel + cisplatin + RTPFSMarch 31, 2025CompletedWang et al. (2020a, b)NCT04005170IIUnresectable ECToripalimab + Paclitaxel + cisplatin + RT–CRRJuly 31, 2022CompletedZhu et al. (2023)NCT04210115IIIESCC/EAC/GEJCPembrolizumab + ICC + RTPlacebo + ICC + RTEFS, OSFebruary, 2027Active, not recruitingShah et al. (2021)NCT04550260IIILocally advanced unresectable ESCCDurvalumab + ICC + RTPlacebo + ICC + RTPFSNovember 30, 2026Active, not recruitingWang et al. (2022a, b)NCT04844385IILocally advanced unresectable ESCCToripalimab + paclitaxel-albumin + nedaplatin + capecitabine + RT (60 Gy)Toripalimab + paclitaxel-albumin + nedaplatin + capecitabine + RT (50 Gy)PFSDecember 20, 2024Active, not recruitingQiu et al. (2024)Consolidative therapyNCT06342167IILocally advanced or early stage ESCCSintilimab + RT + Enteral nutritional emulsion–PFSDecember, 2026Active, not recruitingYuan et al. (2025a, b)NCT04821765IIAdvanced ESCCTislelizumab + triprizumab + cisplatin + albumin paclitaxel + RT–LCRDecember 31, 2024CompletedZheng et al. (2024)EC, esophageal carcinoma; ESCC, esophageal squamous cell carcinoma; EAC, esophageal adenocarcinoma; GEJA, gastroesophageal junction adenocarcinoma; GEJC, esophagogastric junction cancer; RT, radiotherapy; ICC, investigator chosen chemotherapy; FP, capecitabine + cisplatin; pCR, pathologic complete response; OS, overall survival; MPR, major pathological response; PFS, progression-free survival; RFS, relapse-free survival; CR, complete response; AE, adverse events; EFS, event-free survival; CCR, clinical response rate; LCR, locoregional control rate Reported clinical trials investigating the combination of radiotherapy and immune checkpoint inhibitors in esophageal cancer Camrelizumab + carboplatin + albumin paclitaxel Carboplatin + albumin paclitaxel + RT EC, esophageal carcinoma; ESCC, esophageal squamous cell carcinoma; EAC, esophageal adenocarcinoma; GEJA, gastroesophageal junction adenocarcinoma; GEJC, esophagogastric junction cancer; RT, radiotherapy; ICC, investigator chosen chemotherapy; FP, capecitabine + cisplatin; pCR, pathologic complete response; OS, overall survival; MPR, major pathological response; PFS, progression-free survival; RFS, relapse-free survival; CR, complete response; AE, adverse events; EFS, event-free survival; CCR, clinical response rate; LCR, locoregional control rate Neoadjuvant therapy In the field of neoadjuvant therapy, nICRT has been considered as a promising approach. A meta-analysis incorporating 37 studies indicated that nICRT yields superior survival outcomes compared to traditional nCRT in resectable EC. It showed notably enhanced short-term efficacy, particularly in ESCC patients, and a manageable safety profile (Liu et al. 2025b). However, these conclusions are limited by the predominance of small-sample, early-phase trials, potential biases, and insufficient long-term follow-up. Therefore, this approach cannot yet be recommended as standard therapy and should be pursued within clinical trials. Several early-phase clinical trials have provided supporting evidence for nICRT. A single-arm phase Ib trial demonstrated that toripalimab combined with short-course neoadjuvant radiotherapy and chemotherapy was well tolerated and yielded a pathological complete response (pCR) rate of 55% in patients with resectable locally advanced ESCC (Jiang et al. 2024). This study also found that patients with higher pre-treatment T-cell inflammatory signature (TIS) scores were more likely to achieve pCR. Another phase II trial reported (Wang et al. 2024) that among patients with initially unresectable locally advanced ESCC who received CRT followed by tislelizumab as conversion therapy, 66.7% achieved a resectable status. For the adenocarcinoma population, the addition of durvalumab to neoadjuvant chemoradiotherapy has also demonstrated high rates of pathological response and encouraging survival trends (Cowzer et al. 2023). Furthermore, a phase II study investigating sotigalimab (a CD40 agonistic antibody) combined with neoadjuvant CRT showed it significantly enhanced the pCR rate with a manageable safety profile (Ko et al. 2025). This effect is attributed to the activation of various immune cells, thereby inducing anti-tumor immune responses. Collectively, these results underscore that nICRT has great potential in perioperative management, particularly for patients in whom tumor downstaging or enhancing the chance of radical resection is desired. Locally advanced treatment For locally advanced unresectable ESCC, the combination strategies are more diverse, with many trials still ongoing. Induction immunotherapy followed by concurrent chemoradiotherapy has been explored in studies such as ImpactCRT (camrelizumab) and EC-CRT-002 (tislelizumab). Concurrent chemoradiotherapy with immunotherapy is being investigated in multiple trials including KEYNOTE-975 (pembrolizumab), RATIONALE-311 (tislelizumab), ESCORT-CRT (camrelizumab), and EC-CRT-001 (toripalimab), with results eagerly awaited. Consolidation immunotherapy after chemoradiotherapy has shown promise: the phase III SKYSCRAPER-07 study (atezolizumab) reported positive survival outcomes, suggesting this regimen may become a new curative treatment option. In the advanced setting, the combination of radiotherapy and immunotherapy also demonstrates synergistic efficacy. A retrospective analysis of 133 patients with advanced EC treated with sintilimab showed that those who had received RT within the previous 3 months had significantly longer median progression-free survival (PFS) and overall survival (OS) compared to those without RT. A separate randomized phase II trial (Xu et al. 2022a) further confirmed that sintilimab significantly prolonged overall survival as a second-line treatment in patients with advanced or metastatic ESCC. Furthermore, a retrospective study identified RT as a key factor in predicting both OS and PFS, demonstrating that combining ICIs with chemotherapy significantly improved survival in patients with locally advanced or metastatic ESCC (Liu et al. 2025a). It is interesting that some reports also suggest the complexity of these strategies. In advanced ESCC, a phase Ib study investigating a PD-L1/CTLA-4 bispecific antibody in combination with chemotherapy and palliative RT showed a tolerable safety profile and promising efficacy (Zhao et al. 2024). This perspective is further supported by evidence from previous EC trials involving camrelizumab plus RT (Zhang et al. 2021a), camrelizumab plus CRT (Zhang et al. 2021b), atezolizumab plus CRT (Van Den Ende et al. 2021), and sintilimab plus CRT (Liu et al. 2023). Current challenges of radioimmunotherapy Timing and sequence of radioimmunotherapy ICIs function by targeting various stages of the immune response and activating multiple immune cell types. RT also elicits significant immunological changes (Wang et al. 2021). Consequently, determining the optimal sequence and timing of administration is critical for achieving synergistic anti-tumor effects. However, this optimal strategy remains undefined and is likely variable across different multimodal treatment regimens. Studies have found that the expression of immune checkpoint proteins such as PD-1 and PD-L1 is significantly upregulated in esophageal adenocarcinoma cells following RT. Combining anti-PD-1/PD-L1 therapy at this juncture can synergistically and markedly reduce tumor cell activity (Donlon et al. 2022). However, due to the scarcity of relevant studies in EC, insights are often drawn from lung cancer experience, where concurrent immunotherapy and RT may yield superior outcomes compared to sequential administration. A meta-analysis in lung cancer indicated that an interval exceeding 42 days between RT and durvalumab did not affect 12-month OS or PFS; however, a very short interval was associated with an increased incidence of toxic events (Wang et al. 2022b). Conversely, other research has indicated that there is no statistically significant difference in survival benefit between concurrent and sequential administration of RT and ICIs (Welsh et al. 2019). A phase II trial in locally advanced head and neck cancer demonstrated that consolidative ICIs yielded superior outcomes compared to concurrent administration when combined with definitive CRT (Clump et al. 2022). It has been hypothesized that concurrent RT and ICIs may compromise immunotherapy efficacy by inducing lymphopenia, a consequence of immunosuppressive effects and elective nodal irradiation (Rao et al. 2023; Chen et al. 2020). Therefore, additional preclinical and clinical research is warranted to elucidate these discrepancies and establish the optimal sequencing for combining RT and ICIs. Another study reviewing recent phase II clinical trials (Ghalehtaki et al. 2025) noted that the majority employed a concurrent administration strategy, which was associated with high pathological complete response (pCR) rates and a manageable toxicity profile, suggesting a potential synergistic effect between CRT and ICIs. Although induction and consolidative ICI regimens also demonstrated some efficacy, the evidence is less robust than for concurrent therapy, necessitating further validation. Furthermore, although most adverse events associated with combination therapy were tolerable, an analysis indicated that the concurrent approach may lead to a higher incidence of high-grade toxicities compared to sequential treatment. The same analysis also suggested that PD-1 inhibitors might be associated with an increased risk of pneumonitis of any grade compared to PD-L1 inhibitors (Xu et al. 2022b). In conclusion, the optimal timing and sequencing for combining ICIs with RT remain to be fully elucidated through further investigation. RT immunotoxicity By activating immune cells within the TME, such as macrophages and endothelial cells, RT triggers the release of inflammatory cytokines like tumor necrosis factor-alpha (TNF-α) and interleukins (ILs), resulting in both local and systemic inflammation. In clinical practice, RT aims to maximize tumor damage while minimizing harm to adjacent healthy tissues, but some impact on surrounding tissues is inevitable. Radiation-induced damage is characterized by acute and delayed toxicity reactions, which may limit dose escalation and affect treatment outcomes. Acute reactions typically appear within weeks and manifest as skin redness and inflammation, while delayed reactions such as fibrosis and organ dysfunction may appear months or years later. Within hours of radiation exposure, the endothelial and epithelial barriers are damaged, leading to infiltration of inflammatory immune cells that secrete pro-inflammatory cytokines like TNF and IL-6, further activating endothelial cells and exacerbating immune cell recruitment (Lu et al. 2023). RT also upregulates adhesion molecules including ICAM1, VCAM1, and E-selectin, promoting leukocyte trafficking to irradiated tissues (Cytlak et al. 2022). Among EC patients, the most common form of this acute reaction is radiation esophagitis. The direct injury to esophageal epithelial cells triggers the release of inflammatory cytokines, leading to mucosal inflammation, edema, and pain. This inflammatory response is a direct consequence of the endothelial and epithelial barrier damage described above, with infiltrating immune cells amplifying local tissue reaction. When ICIs are combined with RT, this inflammatory response may be intensified, increasing the risk of mucosal ulceration. Following the acute inflammatory phase triggered by RT, the immune response ideally shifts towards resolution without progressing to chronic inflammation. However, late normal tissue toxicity frequently occurs in clinical practice. Severe chronic inflammation usually appears 4–12 weeks after RT, potentially due to immune effects spreading beyond the irradiated area, mitotic mutations, or delayed cell aging (De Ruysscher et al. 2019; Giuranno et al. 2019). In the esophagus, this chronic fibrotic process can lead to the formation of strictures, particularly in patients who have experienced severe acute esophagitis. The repeated cycle of epithelial injury and repair, compounded by TGF-β-driven collagen deposition, results in luminal narrowing and progressive dysphagia. This represents a transition from acute inflammatory injury to chronic structural change. Fibrosis in normal tissues results from activation of fibroblasts and cancer-associated fibroblasts (CAFs), which produce collagen and other extracellular matrix components under the influence of TGF-β (Kalluri 2016). The accumulation of bioactive TGF-β is considered central to late toxicity, linked to recurrent inflammation and fibrosis (Stansborough et al. 2018). Endothelial cell damage following RT increases vascular permeability, promotes inflammatory cell migration, and impairs vascular density and function (Khan et al. 2018). In chest radiation therapy, the lungs are another organ prone to fibrosis. Acute radiation pneumonitis presents with cough and dyspnea, corresponding to inflammatory infiltration and cytokine release in irradiated lung tissue. In severe cases, this progresses to pulmonary fibrosis. When ICIs are combined with thoracic RT, overlapping inflammatory pathways may increase both the incidence and severity of pneumonitis. The radiation-induced late effects on normal tissues depend not only on total dose but also on dose per fraction and the anatomical volume encompassed by the radiation field (Martinez-Zubiaurre et al. 2018). RT-induced chronic inflammation and fibrosis may be linked to genetic factors affecting DNA repair, ROS scavenging, and immune mediators such as TGF-β, TNF, IL-18, or components of the RAS signaling pathway (Cytlak et al. 2022). Therefore, although the combination of RT and immunotherapy is an innovative and promising approach for cancer therapy, the toxicities induced by this treatment are still a major challenge in clinic practice. Therefore, it is of practical significance to understand the toxicities of various immunotherapeutic regimens combined with RT for designing precise treatment protocols. Optimizing the dose and fractionation The optimal radiation dose for EC remains controversial. Currently, 50 Gy is regarded as the recommended dose for definitive RT in esophageal squamous cell carcinoma (ESCC) (Ajani et al. 2015). Furthermore, research indicates that increased radiation doses do not necessarily enhance therapeutic outcomes or improve the clinical prognosis of patients (Worrell et al. 2020; Zhang et al. 2023). Concurrent CRT is the cornerstone treatment for locally advanced EC. However, the toxicities associated with it, such as radiation esophagitis and myelosuppression, often result in treatment discontinuation or dose reduction. This particularly restricts its effectiveness in elderly patients or those with poor performance status. A case report documented that an elderly patient with advanced ESCC received low-dose RT (a total dose of 60 Gy in 50 fractions) combined with immunotherapy and targeted therapy, achieving promising efficacy and tolerability (Yuan et al. 2025b). This approach offers a new therapeutic strategy for patients unable to tolerate standard treatment. Further research suggests that a therapeutic strategy combining low-dose radiotherapy (LD-RT), high-dose radiotherapy (HD-RT), and ICIs may effectively induce an inflammatory tumor immune microenvironment (TIME) in both primary and distant “cold” tumor sites. Research by Chi et al. indicates that the modulation of the immune microenvironment by RT is dependent on the radiation dose and fractionation regimen (Chi and Nguyen 2023). Therefore, the careful selection of radiation dose and fractionation is critical for maximizing the synergistic therapeutic outcome. RT target volume and technique RT can adversely affect the immune system by, for example, reducing circulating lymphocyte counts and impairing immune function. Therefore, determining the most appropriate RT target volume is of significant clinical importance. Currently, elective nodal irradiation (ENI) is recommended for definitive RT. However, growing evidence supports the use of modern imaging-guided involved-field irradiation (IFI) as a RT strategy for EC, in both neoadjuvant and definitive settings (Liu et al. 2019). Compared to ENI, IFI is associated with fewer adverse effects, a lower rate of isolated nodal failure, and satisfactory survival outcomes (Zhu et al. 2021). Consequently, adopting IFI may be more conducive to the efficacy of immunotherapy when combined with RT. Furthermore, as an emerging technique, FLASH radiotherapy (FLASH-RT) delivers ultra-high dose-rate radiation within an extremely short duration. It effectively controls tumors while significantly reducing or even completely avoiding damage to normal tissues (Symonds and Jones 2019). However, the underlying mechanisms behind FLASH-RT’s protective effect on normal tissues and its impact on the surrounding immune microenvironment remain unclear and warrant further investigation. RT resistance ICIs have greatly improved the treatment of advanced EC. However, primary (innate) and acquired (adaptive) resistance result in treatment failure in many patients. Primary resistance mechanisms are complex and involve both intrinsic factors, such as loss of tumor antigens, downregulation of HLA expression, and mutations in signaling pathways within tumor cells, and extrinsic factors, such as the recruitment of immunosuppressive cells, including Tregs and MDSCs, and upregulation of immune checkpoints in the TME (Vaidya et al. 2020). Such mechanisms lead to immune escape (Li et al. 2025b). RT has emerged as a key strategy to reverse resistance and enhance the efficacy of ICIs through its immunomodulatory effects. RT induces ICD and releases DAMPs such as CALR and HMGB1, which in turn can upregulate antigen presentation and activate T cells. In addition, RT can downregulate the immunosuppressive cells in the TME and increase the infiltration of effector T cells, and thereby convert “cold” tumors into “hot” tumors (Galluzzi et al. 2016). Although radiotherapy-induced upregulation of PD-L1 represents a mechanism of immune escape, it can also render tumor cells sensitive to subsequent PD-1/PD-L1 inhibitors (Kordbacheh et al. 2018). Acquired resistance after an initial response to immunotherapy usually involves local progression mainly through two mechanisms: antigen loss and T cell exhaustion (Sharma et al. 2017). In this case, localized RT targeting the progressing lesions not only directly kills tumor cells but also reignites a systemic anti-tumor immune response via the ICD process, effectively functioning as an in situ vaccination. This process, mediated by the activation of pathways like cGAS-STING, has the potential to induce an abscopal effect and control the non-irradiated lesions (Li et al. 2019). However, the clinical translation of combining therapy still faces challenges. A study in non-small cell lung cancer (NSCLC) patients resistant to prior PD-(L)1 therapy showed that combining hypofractionated or low-dose RT with PD-L1/CTLA-4 inhibitors did not significantly improve the response rate (Schoenfeld et al. 2022). This indicated that simply combining RT may not be effective in patients who have previously been exposed to immunotherapy. However, with the development of new strategies such as targeted alpha-particle therapy (TAT) and other radioimmunotherapy approaches, the application of RT in combination with ICIs is receiving huge attention. Constanzo et al. (Constanzo et al. 2022) investigated the immunostimulatory effects of TAT, a novel form of radioimmunotherapy. They found that TAT induced ICD and activated related signaling pathways, and thus could effectively stimulate adaptive immune responses. This provides a new possibility of combining treatment with ICIs, but its efficacy and mechanisms still need to be further investigated. In other words, RT has transcended the range of local treatment effects and has gradually developed into an important means of immunomodulation for overcoming primary and acquired resistance to EC by reversing immune resistance and converting “cold” tumors into “hot” tumors through ICD induction and remodeling of the immune microenvironment, upregulation of immune checkpoint molecules, and stimulation of systemic immune responses. Perspectives With the emergence of ICIs targeting programmed cell death protein 1 (PD-1), PD-L1, and cytotoxic T-lymphocyte-associated protein 4 (CTLA − 4), a new chapter in cancer treatment has begun. These drugs use the body’s own immune system to attack tumors. Combined immunotherapy and radiotherapy have achieved remarkable efficacy in numerous clinical trials for EC, bringing new hope to improve survival and quality of life of patients (Lai et al. 2025). However, combined treatment still confronts challenges such as treatment resistance, immune-related adverse events (irAEs), and limited effectiveness in some patients, which need further investigation. The combination of immunotherapy and RT and/or chemotherapy has revolutionized the treatment of EC. This new treatment strategy can not only improve the therapeutic effect, but also provides new approaches to overcome the limitations of conventional treatment by synergistic effects. Specifically, RT remodels the tumor immune microenvironment by upregulating immune checkpoint molecules (such as PD-L1), and ICIs can further enhance the systemic immune response by amplifying the immune response induced by RT (Xu et al. 2025). The treatment has achieved remarkable success in clinical practice, especially providing more treatment options for patients who are not suitable for traditional high-intensity treatment, such as the elderly and weak patients. In the future, the treatment of EC will gradually develop toward multidisciplinary treatment, precision medicine, and personalized combined treatment. On one hand, we should further explore the combination of radiotherapy and immunotherapy, including the optimization of radiation dose and fractionation, target area (such as IFI), drug selection and the sequence and timing of drug and RT administration, to maximize the synergistic effect and minimize toxicity. On the other hand, we should further explore the “abscopal effect” and its underlying mechanisms, so that more patients can benefit from this treatment. In addition, the continuous emergence of new immunotherapy drugs, combined with RT, will provide more unprecedented opportunities to enhance the anti-tumor immune effect. However, the specific protocols for combining immunotherapy and RT need to be validated in large-scale prospective clinical trials. We believe that more high-quality evidence will promote the clinical application of this combined strategy, thereby improving the survival and quality of life of patients with EC. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Author contributions Yuqing Wang, Junjie Gu searched the literature, constructed the figures and drafted the manuscript; Xinchen Sun conceived the review and made critical revisions of the review. All the authors contributed to the article and approved the final version for submission. Funding The work was supported by Jiangsu Provincial Key Medical Discipline (Laboratory) of Radiation Oncology (Grant No. JSDW202238) and the National Natural Science Foundation of China (Grant Nos. 82073344 and 81874217). Data availability Not applicable. Declarations Conflict of interest The authors declare no competing interests. Ethical approval and consent to participate Not applicable. Consent for publication Not applicable. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Yuqing Wang and Junjie Gu have contributed equally to this work. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement Not applicable.